← Back to Search

Diabetes Education and Management for Diabetes (PROMPT Trial)

N/A
Waitlist Available
Led By Katrina Donahue, MD, MPH
Research Sponsored by University of North Carolina, Chapel Hill
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, month 6

Summary

This trial seeks to improve referral & attendance to diabetes self-management services, by testing the best time points for referral & by conducting a pilot study to compare the effectiveness of peer support.

Who is the study for?
This trial is for adult, English-speaking patients with type 2 diabetes who are referred to Diabetes Self-Management Education and Support (DSMES) classes by primary care providers from the participating practices. Providers not employed at these practices or patients not referred to DSMES from them cannot join.
What is being tested?
The study tests a Best Practice Advisory (BPA) timing strategy to maximize referrals to DSMES services and compares peer support's effectiveness in improving attendance at these services. It involves three steps: optimizing BPA timing, piloting peer support, and planning a larger trial.
What are the potential side effects?
Since this trial focuses on education and management strategies rather than medication, it does not have typical medical side effects. However, participants may experience stress or time constraints due to additional commitments.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, month 6
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, month 6 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Odds of attending 1 DSMES class
Odds of referral for DSMES Placed through the Electronic Health Record (EHR)
Secondary study objectives
A1c - Baseline
Change in A1c from baseline to 3 months
Change in A1c from baseline to 6 months
+10 more

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: 3. Peer SupportExperimental Treatment1 Intervention
45 patients in the 6 clinics who are referred to DSMES classes who enroll in the study will be assigned a peer supporter who will work with the participant and encourage attendance to the DSMES classes in addition to the usual support offered by the clinic.
Group II: 1. Best Practice AdvisoryExperimental Treatment1 Intervention
Four practices receive a suite of tools intended to increase the rate of referral to DSMES classes for patients with type 2 diabetes. In these four practices, the assigned DCE specialist will have access to a list of eligible patients who have upcoming appointments with their primary care providers. The DCE specialist will message the providers about the eligible patients via the EHR. They will also place a pended order for referral to DSMES class for the eligible patients. The health care provider will be able to either approve or deny the order for the referral Additionally, when an eligible patient presents for an appointment in one of the four intervention clinics, a best practice advisory (BPA) will fire within the EHR and encourage the provider to place a referral for DSMES classes.
Group III: 4. Usual CarePlacebo Group1 Intervention
45 patients in the 6 clinics who are referred to DSMES classes who enroll in the study will receive the usual support offered by the clinic.
Group IV: 2. Silent Best Practice AdvisoryPlacebo Group1 Intervention
Two practices will not receive the suite of tools, but the lists and BPA will be created and sent to the research team.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Best Practice Advisory
2022
N/A
~7390
Peer Support
2011
N/A
~6610

Find a Location

Who is running the clinical trial?

University of North Carolina, Chapel HillLead Sponsor
1,561 Previous Clinical Trials
4,298,691 Total Patients Enrolled
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
2,455 Previous Clinical Trials
4,335,018 Total Patients Enrolled
Katrina Donahue, MD, MPHPrincipal InvestigatorUNC Chapel Hill
Laura Young, MD, PhDPrincipal InvestigatorUNC Chapel Hill

Media Library

1. Best Practice Advisory Clinical Trial Eligibility Overview. Trial Name: NCT05587348 — N/A
Type 2 Diabetes Research Study Groups: 4. Usual Care, 2. Silent Best Practice Advisory, 1. Best Practice Advisory, 3. Peer Support
Type 2 Diabetes Clinical Trial 2023: 1. Best Practice Advisory Highlights & Side Effects. Trial Name: NCT05587348 — N/A
1. Best Practice Advisory 2023 Treatment Timeline for Medical Study. Trial Name: NCT05587348 — N/A
Type 2 Diabetes Patient Testimony for trial: Trial Name: NCT05587348 — N/A
~0 spots leftby Dec 2024